First report of safety and efficacy of a glycoPEGylated FVIII (N8-GP) in previously treated pediatric patients with severe hemophilia A—results from the international phase 3 pathfinder^TM5 trial

¹Centre for Haemostasis and Thrombosis, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom;

²Novo Nordisk A/S, Søborg, Denmark;

³Department of Hematology, Ogikubo Hospital, Suginami-ku, Tokyo, Japan;

⁴National Blood Centre, Kuala Lumpur, Malaysia;

⁵Ege University Children's Hospital, Department of Hematology, Izmir, Turkey;

⁶Pappajohn Biomedical Institute, and Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, USA;

⁷Institute of Blood Pathology and Transfusion Medicine, Ukrainian National Academy of Medical Sciences, Lviv, Ukraine;

⁸Department of Pediatrics, Hematology-Oncology Section, Baylor College of Medicine, Houston, USA; and

⁹Children's Hospital, affillate of Vilnius University Hospital Santariskiu klinikos, Centre for Pediatric Oncology and Hematology, Vilnius, Lithuania